Clinical data of patients with disease recurrence.

Clinical data of patients with disease recurrence.

<p>Clinical data of patients with disease recurrence.</p>

Saved in:

Bibliographic Details
Main Author:	Mengzhi Cheng (22648018) (author)
Other Authors:	Jianbin Zhang (230061) (author), Lili Jin (2869598) (author), Caihua Yu (715599) (author), Zhonghai Xie (22648021) (author), Dong Li (212687) (author), Qinhua Gu (361108) (author), Qibin Shen (9470343) (author)
Published:	2025
Subjects:	Medicine Cell Biology Cancer Biological Sciences not elsewhere classified osimertinib upon identification corin trial indicated central nervous system 2 adverse events retrospective study evaluated higher aes occurred although overall survival potential dfs benefit enrolled 37 patients completely resected egfr year dfs rate year disease study suggests free survival aes ), tolerated profile successfully switched risk factors nsclc ). evidence regarding adjuvant icotinib 4 %. 31 months
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Clinical characteristics of patients (n = 37).
by: Mengzhi Cheng (22648018)
Published: (2025)

Adverse events.
by: Mengzhi Cheng (22648018)
Published: (2025)

Representative images of two patients successfully treated with osimertinib following acquired resistance to icotinib.
by: Mengzhi Cheng (22648018)
Published: (2025)

Kaplan-Meier curve for DFS rate.
by: Mengzhi Cheng (22648018)
Published: (2025)

Distribution of EGFR mutations, surgical approaches, and high-risk factors in this cohort.
by: Mengzhi Cheng (22648018)
Published: (2025)

Patient enrollment flowchart.
by: Mengzhi Cheng (22648018)
Published: (2025)

Table 1_Prognostic significance of prognostic nutritional index in patients with head and neck squamous cell carcinoma.docx
by: Yongping Wang (66268)
Published: (2025)

Grade 3–5 adverse events (incidence rate > 1% in the PPI group).
by: Hai Huang (140371)
Published: (2024)

Any grade adverse events (incidence rate > 10% in the PPI group).
by: Hai Huang (140371)
Published: (2024)

Subgroup analysis of event-free survival.
by: Hai Huang (140371)
Published: (2024)

Summary of adverse events.
by: Hai Huang (140371)
Published: (2024)

Baseline characteristics of the included studies.
by: Hai Huang (140371)
Published: (2024)

Fig 5 -
by: Hai Huang (140371)
Published: (2024)

Forest plots of pathological responses associated with PPI versus chemotherapy.
by: Hai Huang (140371)
Published: (2024)

Comparisons of OSR and EFSR.
by: Hai Huang (140371)
Published: (2024)

Forest plots of overall survival and event-free survival associated with PPI versus chemotherapy.
by: Hai Huang (140371)
Published: (2024)

Extract data details.
by: Hai Huang (140371)
Published: (2024)

Flow chart.
by: Hai Huang (140371)
Published: (2024)

S6 Fig -
by: Hai Huang (140371)
Published: (2024)

Forest plots of safety summary associated with PPI versus chemotherapy.
by: Hai Huang (140371)
Published: (2024)

Forest plots of surgery summary associated with PPI versus chemotherapy.
by: Hai Huang (140371)
Published: (2024)

Forest plots of EFSR at 6–48 months associated with PPI versus chemotherapy.
by: Hai Huang (140371)
Published: (2024)

Forest plots of OSR at 12–48 months associated with PPI versus chemotherapy.
by: Hai Huang (140371)
Published: (2024)

Cochrane risk assessment.
by: Hai Huang (140371)
Published: (2024)

The timeline showing patient recruitment and measurement timeframes for outcome measures.
by: Feza Karakayali (22566866)
Published: (2025)

Database draft.
by: Feza Karakayali (22566866)
Published: (2025)

<b>低 lncRNA BLACAT1 </b><b> </b><b>microRNA-212-5p/EGFR 轴逆转奥希替尼对非小细胞肺癌的耐药性通过</b><b>microRNA-212-5p/EGFR 轴逆转非小细胞肺癌</b>
by: Baodan Yu (22246555)
Published: (2025)

Table 1_Assembly factor for spindle microtubules (ASPM) promotes osimertinib resistance in lung cancer by increasing EGFR stability.docx
by: Pengpeng Gui (22186243)
Published: (2025)

Data Sheet 1_Assembly factor for spindle microtubules (ASPM) promotes osimertinib resistance in lung cancer by increasing EGFR stability.pdf
by: Pengpeng Gui (22186243)
Published: (2025)

Data Sheet 2_Assembly factor for spindle microtubules (ASPM) promotes osimertinib resistance in lung cancer by increasing EGFR stability.pdf
by: Pengpeng Gui (22186243)
Published: (2025)

Data Sheet 3_Assembly factor for spindle microtubules (ASPM) promotes osimertinib resistance in lung cancer by increasing EGFR stability.pdf
by: Pengpeng Gui (22186243)
Published: (2025)

Data Sheet 4_Assembly factor for spindle microtubules (ASPM) promotes osimertinib resistance in lung cancer by increasing EGFR stability.pdf
by: Pengpeng Gui (22186243)
Published: (2025)

Data Sheet 5_Assembly factor for spindle microtubules (ASPM) promotes osimertinib resistance in lung cancer by increasing EGFR stability.pdf
by: Pengpeng Gui (22186243)
Published: (2025)

Data Sheet 6_Assembly factor for spindle microtubules (ASPM) promotes osimertinib resistance in lung cancer by increasing EGFR stability.pdf
by: Pengpeng Gui (22186243)
Published: (2025)

Data Sheet 7_Assembly factor for spindle microtubules (ASPM) promotes osimertinib resistance in lung cancer by increasing EGFR stability.pdf
by: Pengpeng Gui (22186243)
Published: (2025)

Data Sheet 8_Assembly factor for spindle microtubules (ASPM) promotes osimertinib resistance in lung cancer by increasing EGFR stability.pdf
by: Pengpeng Gui (22186243)
Published: (2025)

Data Sheet 9_Assembly factor for spindle microtubules (ASPM) promotes osimertinib resistance in lung cancer by increasing EGFR stability.pdf
by: Pengpeng Gui (22186243)
Published: (2025)

Data Sheet 10_Assembly factor for spindle microtubules (ASPM) promotes osimertinib resistance in lung cancer by increasing EGFR stability.pdf
by: Pengpeng Gui (22186243)
Published: (2025)

Data Sheet 11_Assembly factor for spindle microtubules (ASPM) promotes osimertinib resistance in lung cancer by increasing EGFR stability.pdf
by: Pengpeng Gui (22186243)
Published: (2025)

Data Sheet 12_Assembly factor for spindle microtubules (ASPM) promotes osimertinib resistance in lung cancer by increasing EGFR stability.pdf
by: Pengpeng Gui (22186243)
Published: (2025)

Cannot write session to /tmp/vufind_sessions/sess_ksgubpckes6ules8p9861a387i